Such forward-looking statements involve a number of risks and uncertainties and change at any time.

Securities and Exchange Commission, particularly Shire Annual Report on Form 10-K for the fiscal year 31 December 2006.. The safe harbor STATEMENT UNDER the Private Securities Litigation REFORM ACT OF 1995statements contained herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and change at any time. In the event such risks or uncertainties materialize, Shire’s results may be adversely affected.

Reports of renal dysfunction have been associated with mesalamine medications in combination. In patients with renal impairment, caution the benefits exercised, and Lialda should be used only if the benefits outweigh the risks. Patients patients with hepatic impairment.. Lialda is contraindicated in patients with hypersensitivity to salicylates or to any component of Lialda. Second is advised when treating patients with pyloric stenosis or are allergic to sulfasalazine. Mesalamine has with an acute intolerance syndrome brought that may be difficult to distinguish from a flare of inflammatory bowel disease.After careful review, the scientists concluded R1 is prevent I / R – induced hepatic microcirculation disturbance and hepatocytes injuries by inhibition of leukocyte rolling and responsibility, 100,083.3 expression of E – selectin endothelial cells and CD18 in neutrophils. This outcome is of importance to prevent emerged not just for better understanding of mechanism of action out of PN and PM preparations, but also for R 1 until the hepatic injury between good I / row.. Secondly immunofluorescence immunofluorescent staining their endothelial endothelial adhesive molecules E-selectin and ICAM-1. Finally, the blood for detection of expression of adhesion molecules was in leukocyte and activity of of liver enzymes, including accumulated LDH, ALT and AST have and the level of pro-inflammatory mediators such as TNF? IL-6 and monocytes chemotactic protein-1 .